Product image of Methylprednisolon Hikma (Methylprednisolone Sodium Succinate) supplied by GNH India

Methylprednisolon Hikma

Active Ingredient:
Methylprednisolone Sodium Succinate
Origin:
EU

Methylprednisolon Hikma (Methylprednisolone Sodium Succinate)

Methylprednisolone sodium succinate, the active ingredient in Methylprednisolon Hikma, is a corticosteroid presented as an injectable solution for intramuscular and intravenous use. It treats severe allergic reactions, acute asthma exacerbations, rheumatic and musculoskeletal disorders, immunosuppression in transplant patients, and other acute inflammatory conditions.

GNH India supplies Methylprednisolon Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methylprednisolon Hikma is a glucocorticoid used to manage inflammatory and immune‑mediated conditions.

  • Severe allergic reactions: rapid reduction of airway swelling and systemic inflammation.
  • Acute asthma exacerbations: improves airflow by decreasing bronchial inflammation.
  • Rheumatic and musculoskeletal disorders: alleviates pain and swelling in joints.
  • Immunosuppression in transplant patients: prevents organ rejection by dampening immune response.
  • Acute inflammatory conditions: controls severe inflammation in various tissues.

How It Works

  • Methylprednisolone sodium succinate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and reduces vascular permeability, resulting in potent anti‑inflammatory and immunosuppressive effects.

Side Effects

Adverse reactions may occur with systemic glucocorticoid therapy.

Common Side Effects

  • Hyperglycemia: elevated blood sugar levels.
  • Fluid retention: swelling of extremities.
  • Hypertension: increased blood pressure.
  • Mood changes: irritability or euphoria.
  • Insomnia: difficulty sleeping.
  • Increased appetite and weight gain.

Serious or Rare Side Effects

  • Adrenal suppression: reduced endogenous cortisol production.
  • Severe infection: heightened susceptibility to bacterial, viral, or fungal infections.
  • Gastrointestinal bleeding or ulceration.
  • Avascular necrosis of bone.
  • Psychosis or severe mood disorders.
  • Anaphylactic reactions.

Precautions & Warnings

Careful monitoring and risk assessment are essential when using systemic corticosteroids.

  • Infection risk: evaluate for active infections before initiating therapy.
  • Blood glucose: monitor diabetic patients closely for hyperglycemia.
  • Bone health: assess osteoporosis risk and consider prophylaxis.
  • Dose minimisation: use the lowest effective dose for the shortest duration.
  • Discontinuation: taper gradually to avoid adrenal crisis.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methylprednisolon Hikma can alter the effects of several concomitant medications.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase steroid exposure.
  • Live vaccines: risk of uncontrolled infection.
  • NSAIDs: heightened risk of gastrointestinal bleeding.
  • Anticoagulants: enhanced anticoagulant effect leading to bleeding.
  • Oral hypoglycemics: may exacerbate hyperglycemia.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce steroid efficacy.
  • ACE inhibitors or ARBs: potential for potassium imbalance.
  • Diuretics: may affect fluid and electrolyte balance.
  • Azole antifungals: moderate increase in steroid levels.
  • Non‑live vaccines: monitor immune response.

Frequently Asked Questions

Methylprednisolon Hikma is indicated for severe allergic reactions, acute asthma exacerbations, rheumatic and musculoskeletal disorders, immunosuppression in organ‑transplant patients, and other acute inflammatory conditions where rapid anti‑inflammatory control is required.

The drug binds to intracellular glucocorticoid receptors, altering gene transcription to suppress pro‑inflammatory cytokines, reduce leukocyte migration, and decrease vascular permeability, thereby providing potent anti‑inflammatory and immunosuppressive effects.

Dosing is individualized and determined by the prescribing clinician based on the specific indication, severity of disease, patient weight, and response. The product is supplied as an injectable solution for intramuscular or intravenous administration.

The pregnancy category for methylprednisolone sodium succinate is unknown. Use only if the potential benefit justifies the potential risk to the fetus. Caution is advised during breastfeeding, as the drug may be excreted in milk.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methylprednisolon Hikma is a synthetic glucocorticoid with high anti‑inflammatory potency and a relatively rapid onset when given intravenously. Compared with hydrocortisone, it has greater glucocorticoid activity and less mineralocorticoid effect, making it suitable for severe inflammatory emergencies.

The injectable solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the product in its original packaging until use.

Methylpredisolon Hikma is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration technique and rate are determined by the prescriber according to the clinical situation.

Serious risks include adrenal suppression, severe infections, gastrointestinal bleeding, avascular necrosis, and psychiatric disturbances such as psychosis. Patients should be monitored closely for signs of these complications.

Patients with known hypersensitivity to methylprednisolone or any component of the formulation, those with systemic fungal infections, and individuals receiving live vaccines should avoid this product unless specifically directed by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.